Alembic Pharmaceuticals Limited — PPTs, 05-02-2026: Investor Presentation

Alembic Pharma's Q3 FY26 & 9M financial update shows robust performance in key segments.

1. **Business Performance:** International Generics led growth, with Q3 sales up 17% to 954 Cr and 9M sales up 20% to 2,754 Cr, fueled by strong gains in Australia, Europe & ROW, and Canada. The US market also contributed positively. Domestic Branded Formulations grew 6% in Q3 to 652 Cr and 5% in 9M to 1,890 Cr, notably driven by the Animal Health segment. The API business posted moderate growth, up 2% in Q3 to 263 Cr and 6% in 9M to 837 Cr.

2. **Growth Drivers or Strategy:** The company expanded its US presence with 2 new product launches in Q3 FY26, and plans 7 more for Q4. It filed 5 new ANDAs this year, contributing to its pipeline of 270 total ANDAs with 212 final approvals. Domestically, 9 new brands were launched in 9M FY26.

3. **Recent Developments:** (Covered in Growth Drivers above through product launches.)

4. **Key Financial Metrics:** (Integrated into Business Performance above.)

5. **Management Commentary / Outlook:** This investor presentation did not include specific management commentary or forward-looking outlook.